Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6665274 | 1.00 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3NPC1RAB9A | |
| SCHEMBL5866364 | 0.91 | TACR2 (0.47) | SLC6A2SLC6A4SLC6A3NPC1RAB9A | |
| SCHEMBL7045680 | 0.91 | TACR2 (0.47) | SLC6A2SLC6A4SLC6A3NPC1RAB9A | |
| SCHEMBL5866425 | 0.85 | NPC1 (0.49) | SLC6A2SLC6A4SLC6A3NPC1RAB9A | |
| SCHEMBL6161768 | 0.85 | NPC1 (0.49) | SLC6A2SLC6A4SLC6A3NPC1RAB9A | |
| SCHEMBL6663261 | 0.82 | CYP3A4 (0.41) | SLC6A2SLC6A4SLC6A3NPC1RAB9A | |
| SCHEMBL6663255 | 0.82 | CYP3A4 (0.41) | SLC6A2SLC6A4SLC6A3NPC1RAB9A | |
| SCHEMBL8554659 | 0.81 | HPGD (0.45) | SLC6A2SLC6A4SLC6A3NPC1RAB9A | |
| SCHEMBL5866431 | 0.78 | MCHR1 (0.44) | SLC6A2SLC6A4SLC6A3HPGDSMN1; SMN2 | |
| SCHEMBL9078698 | 0.76 | CYP3A4 (0.42) | SLC6A2SLC6A4SLC6A3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248914-A1 | Method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | US | disclosed |
| EP-1450805-A1 | METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003037341-A1 | METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248914-A1 | Method for the treatment of overactive bladder | TACR1, TACR2, OGFR | SLC6A2 329/4885SLC6A4 527/4885SLC6A3 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.